Prostate Cancer and Diseases of the Prostate - Center for Prostate Disease Research

11. The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > 40 ng/mL.
Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, and Moul JW:
Urol. Onc. 7:167-172, 2002.

12. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1024-38,1042; discussion 1042, 1047-8, 1051, 2002.

13. Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis.
Henderson CG, Griewe GL, Siegel TS, Peppas DS, Esther TA, Moul JW:
J Urol. 168:638-9, 2002.

14. Curcumin Down-Regulates AR Gene Expression and Activation in Prostate Cancer Cell Lines.
Nakamura K, Yasunaga Y, Segawa T, Ko D, Moul JW, Srivastava S and Rhim JS:
Int J of Oncol., 21:825-830, 2002.

15. A novel gene DERPC located on 16q22.1 inhibits prostate tumor cell growth and its expression is decreased in prostate and renal tumors.
Sun M, Ma L, Xu L, Li J, Zhang W, Petrovics G, Makarem M, Sesterhenn I, Zhang M, Blanchette-Mackie EJ, Moul JW, Srivastava S and Zou Z:
Molecular Medicine 8: 654-662, 2002.

16. Cadmium-induced neoplastic transformation of human prostate epithelial cells.
Nakamura K, Yasunaga Y, Ko D, Xu LL, Moul JW, Peehl DM, Srivastava S, Rhim JS.
Int J Oncol. 20:543-7, 2002.

17. Prostate biopsy quantitative histology as a staging and prognostic factor.
Moul JW.
J Urol. 167:526-7, 2002.

18. Outcome research: prostate cancer databases.
Moul JW:
Urol Oncol, 7:39-42, 2002.

19. Prostate-specific antigen as a marker of disease activity in prostate cancer.
Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG, Scher HI:
Oncology (Huntingt), 16:1218-24, 2002.

20. Contralateral testicular biopsy procedure in-patients with unilateral testis cancer: is it indicated?
Heidenreich A, Moul JW:
Semin Urol Oncol, 20:234-8, 2002.